Screening for prostate cancer: Early detection or overdetection?

Annual Review of Medicine

Volumn 63, Issue , 2012, Pages 161-170

  Vickers, Andrew J ^a   Roobol, Monique J ^b   Lilja, Hans ^a,c,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Prostate specific antigen (PSA); Prostatic neoplasms; Radiotherapy; Surgery

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD SAMPLING; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; CONTAMINATION; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW; UNITED STATES;

EARLY DIAGNOSIS; HUMANS; MALE; MASS SCREENING; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNNECESSARY PROCEDURES;

EID: 84855953876     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050710-134421     Document Type: Review

References (48)

1. Jemal A, Siegel R, Xu J, et al. 2010. Cancer statistics, 2010. CA Cancer J. Clin. 60:277-300
2. Thompson IM, Lucia MS, Tangen CM. 2007. The ubiquity of prostate cancer: echoes of the past, implications for the present.Commentary. Int. J. Epidemiol. 36:287-89
3. Haas GP, Delongchamps NB, Jones RF, et al. 2007. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J. Natl. Cancer Inst. 99:1484-89
4. Penson DF, McLerran D, Feng Z, et al. 2005. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J. Urol. 173:1701-5 (Pubitemid 40524809)
5. Lilja H, Christensson A, Dahĺen U, et al. 1991. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37:1618-25 (Pubitemid 21905228)
6. Lilja H, Ulmert D, Vickers AJ. 2008. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8:268-78 (Pubitemid 351430866)
7. Concato J, Wells CK, Horwitz RI, et al. 2006. The effectiveness of screening for prostate cancer: a nested case-control study. Arch. Intern. Med. 166:38-43 (Pubitemid 43063839)
8. Roehl KA, Eggener SE, Loeb S, et al. 2006. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol. Oncol. 24:465-71 (Pubitemid 44810008)
9. Lu-Yao G, Albertsen PC, Stanford JL, et al. 2008. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J. Gen. Intern. Med. 23:1809-14
10. Draisma G, Etzioni R, Tsodikov A, et al. 2009. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl. Cancer Inst. 101:374-83
11. Andriole GL, Crawford ED, Grubb RL 3rd, et al. 2009. Mortality results from a randomized prostatecancer screening trial. N. Engl. J. Med. 360:1310-19
12. Schröder FH, Hugosson J, Roobol MJ, et al. 2009. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360:1320-28
13. Ilic D, O'Connor D, Green S, Wilt TJ. 2011. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int. 107:882-91
14. Djulbegovic M, Beyth RJ, Neuberger MM, et al. 2010. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341:c4543
15. Savage CJ, Lilja H, Cronin AM, et al. 2010. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol. Biomarkers Prev. 19:1201-7
16. Labrie F, Candas B, Dupont A, et al. 1999. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38:83-91 (Pubitemid 29052946)
17. Sandblom G, Varenhorst E, Lofman O, et al. 2004. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur. Urol. 46:717-23; discussion 24 (Pubitemid 39488400)
18. Hugosson J, Carlsson S, Aus G, et al. 2010. Mortality results from the Goteborg randomised populationbased prostate-cancer screening trial. Lancet. Oncol. 11:725-32
19. Drazer MW, Huo D, Schonberg MA, et al. 2011. Population-based patterns and predictors of prostatespecific antigen screening among older men in the United States. J. Clin. Oncol. 29:1736-43
20. Jonsson H, Holmström B, Duffy SW, et al. 2010. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int. J. Cancer. 129:1881-88
21. Schröder FH, Roobol MJ. 2010. ERSPC and PLCO prostate cancer screening studies: What are the differences? Eur. Urol. 58:46-52
22. Barry MJ. 2009. Screening for prostate cancer-the controversy that refuses to die. N. Engl. J. Med. 360:1351-54
23. Wolters T, Roobol MJ, Steyerberg EW, et al. 2010. The effect of study arm on prostate cancer treatment in the large screening trial ERSP C. Int. J. Cancer 126:2387-93
24. Newschaffer CJ, Otani K, McDonald MK, et al. 2000. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J. Natl. Cancer Inst. 92:613-21 (Pubitemid 30321303)
25. van Leeuwen PJ, Kranse R, Hakulinen T, et al. 2010. Disease-specific mortality may underestimate the total effect of prostate cancer screening. J. Med. Screen. 17:204-10
26. Vickers AJ, Lilja H. 2009. Prostate cancer: estimating the benefits of PSA screening. Nat. Rev. Urol. 6:301-3
27. Eastham JA, Riedel E, Scardino PT, et al. 2003. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289:2695-700 (Pubitemid 37430140)
28. Christensson A, Bruun L, Björk T, et al. 2011. Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. BJU Int. 107:1769-74
29. Zackrisson B, Ulleryd P, Aus G, et al. 2003. Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. Urology 62:278-81 (Pubitemid 36952077)
30. Thompson IM, Ankerst DP, Chi C, et al. 2005. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3. 0 ng/ml or lower. JAMA 294:66-70 (Pubitemid 41002840)
31. Vickers AJ, Cronin AM, Bjork T, et al. 2010. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341:c4521
32. Begg CB, Riedel ER, Bach PB, et al. 2002. Variations in morbidity after radical prostatectomy. N. Engl. J. Med. 346:1138-44 (Pubitemid 34984605)
33. Vickers AJ, Bianco FJ, Serio AM, et al. 2007. The surgical learning curve for prostate cancer control after radical prostatectomy. J. Natl. Cancer Inst. 99:1171-77 (Pubitemid 47233067)
34. Zietman AL, DeSilvio ML, Slater JD, et al. 2005.Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294:1233-39 (Pubitemid 41352111)
35. Klotz L, Zhang L, Lam A, et al. 2010. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28:126-31
36. Lilja H, Cronin AM, Dahlin A, et al. 2011. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117:1210-19
37. Bul M, van Leeuwen PJ, Zhu X, et al. 2011. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3. 0 ng/ml who are participating in ERSPC Rotterdam. Eur. Urol. 59:498-505
38. van Leeuwen PJ, Connolly D, Tammela TL, et al. 2010. Balancing the harms and benefits of early detection of prostate cancer. Cancer 116:4857-65
39. Vickers A, Cronin A, Roobol M, et al. 2010. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J. Clin. Oncol. 28:2493-98
40. Schroder FH, van der Maas P, Beemsterboer P, et al. 1998. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer Inst. 90:1817-23 (Pubitemid 28559894)
41. Lu-Yao GL, Albertsen PC, Moore DF, et al. 2009. Outcomes of localized prostate cancer following conservative management. JAMA 302:1202-9
42. Roddam AW, Duffy MJ, Hamdy FC, et al. 2005. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur. Urol. 48:386-99; discussion 398-99
43. Vickers AJ, Gupta A, Savage CJ, et al. 2011. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol. Biomarkers Prev. 20:255-61
44. Catalona WJ, Partin AW, Sanda MG, et al. 2011. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2. 0 to 10. 0 ng/ml prostate specific antigen range. J. Urol. 185:1650-55
45. Roobol MJ, Schröder FH, van Leeuwen P, et al. 2010. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a firstline diagnostic test. Eur. Urol. 58:475-81
46. Salami SS, Schmidt F, Laxman B, et al. 2011.Combining urinary detection of TMPRSS2:ERG and CaP3 with serum PSA to predict diagnosis of prostate cancer. Urol. Oncol. In press
47. Cooperberg MR, Broering JM, Kantoff PW, et al. 2007. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J. Urol. 178:S14-19 (Pubitemid 47224952)
48. Savage CJ, Vickers AJ. 2009. Low annual caseloads of United States surgeons conducting radical prostatectomy. J. Urol. 182:2677-79